ATRX represses alternative lengthening of telomeres
Metrics: PDF 2538 views | HTML 2735 views | ?
Christine E. Napier1, Lily I. Huschtscha1, Adam Harvey2, Kylie Bower1, Jane R. Noble1, Eric A. Hendrickson2 and Roger R. Reddel1,2
1 Cancer Research Unit, Children’s Medical Research Institute, The University of Sydney, Westmead, NSW, Australia
2 Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota Medical School, Minneapolis, MN, USA
Roger R. Reddel, email:
Keywords: ATRX, ALT, telomere, immortalization
Received: December 18, 2014 Accepted: March 20, 2015 Published: April 15, 2015
The unlimited proliferation of cancer cells requires a mechanism to prevent telomere shortening. Alternative Lengthening of Telomeres (ALT) is an homologous recombination-mediated mechanism of telomere elongation used in tumors, including osteosarcomas, soft tissue sarcoma subtypes, and glial brain tumors. Mutations in the ATRX/DAXX chromatin remodeling complex have been reported in tumors and cell lines that use the ALT mechanism, suggesting that ATRX may be an ALT repressor. We show here that knockout or knockdown of ATRX in mortal cells or immortal telomerase-positive cells is insufficient to activate ALT. Notably, however, in SV40-transformed mortal fibroblasts ATRX loss results in either a significant increase in the proportion of cell lines activating ALT (instead of telomerase) or in a significant decrease in the time prior to ALT activation. These data indicate that loss of ATRX function cooperates with one or more as-yet unidentified genetic or epigenetic alterations to activate ALT. Moreover, transient ATRX expression in ALT-positive/ATRX-negative cells represses ALT activity. These data provide the first direct, functional evidence that ATRX represses ALT.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.